FDA's top drug regulator quits
Digest more
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...
Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...
Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.
A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...
The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive ...
The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a company’s stock as part of an alleged revenge plot against a former colleague ...
New professional guidance to the nation's pediatricians advises against using a drug in children with autism that many families are clamoring for after it was hyped by federal officials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback